Tyenne® (tocilizumab-aazg) – First-time biosimilar launch

- On April 15, 2024, Fresenius Kabi announced the launch of Tyenne (tocilizumab-aazg) intravenous infusion, a biosimilar to Roche's Actemra (tocilizumab).
    - Tyenne is also FDA-approved as a subcutaneous injection. Launch of this product is pending.
    - In addition, Biogen's Tofidence (tocilizumab-bavi) received FDA approval of its intravenous infusion. Launch of this biosimilar product is pending.
- Tyenne and Actemra share the following indications in adult patients:
    - Moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs
    - Giant cell arteritis.
- Tyenne and Actemra share the following indications in patients 2 years of age and older:
    - Active polyarticular juvenile idiopathic arthritis
    - Active systemic juvenile idiopathic arthritis.
- Actemra is also indicated for the following:
    - Slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease
    - Chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome in adults and pediatric patients 2 years of age and older
    - Coronavirus disease 2019 in hospitalized adult patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation.
- Like Actemra, Tyenne carries a boxed warning for risk of serious infections.